OmniAb To Present High-Throughput Single B-cell Screening xPloration Data At The 20th Annual PEGS Boston Summit

5/15/24 4:28:26 PM ET

Biotechnology: Commercial Physical & Biological Resarch

Health Care

Get the next $OABI alert in real time by email

Technical synergies between xPloration, OmniFlic®, OmniClic® and OmniDeep®

enable new bispecific antibody discovery workflows for OmniAb's partners

OmniAb, Inc. (NASDAQ:OABI) today announced its participation in the 20th Annual PEGS Boston – The Essential Protein & Antibody Engineering Summit underway at the Omni Hotel. Earlier today the Company presented an overview of xPloration, a high-throughput single B-cell screening platform that leverages machine learning and Artificial Intelligence (AI), in a presentation titled "Deep Screening in Harmony with Artificial Intelligence for Bispecific Antibody Discovery."

Get the next $OABI alert in real time by email

Crush Q1 2026 with the Best AI Superconnector

Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

AI-Powered Inbox

Context-aware email replies

Strategic Decision Support

Get Started with Standout.work

Recent Analyst Ratings for
$OABI

Date	Price Target	Rating	Analyst
11/29/2023	$6.00	Outperform	RBC Capital Mkts
4/21/2023	$8.00	Buy	The Benchmark Company
4/13/2023	$10.00	Buy	Craig Hallum
2/22/2023	$10.00	Outperform	Cowen
2/13/2023	$11.00	Buy	H.C. Wainwright

More analyst ratings

OmniAb to Report Fourth Quarter 2025 Financial Results on March 4

OmniAb, Inc. (NASDAQ:OABI) will report financial results for the quarter and year ended December 31, 2025, after the close of the U.S. financial markets on Wednesday, March 4, 2026, and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Conference Call and Webcast Information What: OmniAb conference call to discuss fourth quarter 2025 financial results and business updates Date: Wednesday, March 4, 2026 Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time) Phone: U.S. (800) 549-8228

2/19/26 8:00:00 AM ET

$OABI

Biotechnology: Commercial Physical & Biological Resarch

Health Care

Launch of OmniUltra Expands OmniAb's Reach into New Markets and Applications, Advances Leadership in Antibody Discovery Technologies

First and only transgenic chicken platform engineered to express ultralong CDRH3 domains on a human antibody framework broadens therapeutic opportunities beyond conventional antibodies OmniUltra Virtual Investor Event begins at 5:00 p.m. Eastern time today OmniAb, Inc. (NASDAQ:OABI) announces the launch of its new OmniUltra™ platform, the industry's first and only transgenic chicken engineered to express ultralong CDRH3 domains on a human antibody framework, at the 2025 Antibody Engineering & Therapeutics (AET) Conference underway in San Diego. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215018419/en/ OmniUltra is a versa

12/15/25 4:05:00 PM ET

$OABI

Biotechnology: Commercial Physical & Biological Resarch

Health Care

Platform Technologies Drive $211B Surge in Precision Cancer Treatment

Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Dec. 11, 2025 /PRNewswire/ -- Equity Insider News Commentary – November's wave of FDA oncology approvals signals the industry's shift toward platform-based precision therapies over broad-spectrum approaches[1]. The global anticancer drug market now values immunotherapies at over 45% of total cancer drug revenues, reflecting investor confidence in technologies that engineer specific biological outcomes[2]. Companies deploying proprietary platforms to target previously undruggable proteins are capturing premium valuations as the sector pivots toward modularity and rapid reuse of validated mechanisms, creating momentum for GT Biopharma, Inc.

12/11/25 10:17:00 AM ET

$ERAS

$FHTX

$GTBP

Biotechnology: Pharmaceutical Preparations

Health Care

Biotechnology: Commercial Physical & Biological Resarch

Biotechnology: Biological Products (No Diagnostic Substances)

$OABI
Financials

Live finance-specific insights

View All

OmniAb to Report Fourth Quarter 2025 Financial Results on March 4

2/19/26 8:00:00 AM ET

$OABI

Biotechnology: Commercial Physical & Biological Resarch

Health Care

Launch of OmniUltra Expands OmniAb's Reach into New Markets and Applications, Advances Leadership in Antibody Discovery Technologies

12/15/25 4:05:00 PM ET

$OABI

Biotechnology: Commercial Physical & Biological Resarch

Health Care

OmniAb to Hold OmniUltra Virtual Investor Event on December 15

OmniAb, Inc. (NASDAQ:OABI) today announced it will hold a virtual investor event to showcase the launch of OmniUltra™ on Monday, December 15, 2025, beginning at 5:00 p.m. Eastern time. The event is expected to last approximately one hour and will include a review of OmniAb's newest technology offering, OmniUltra, the industry's only transgenic chicken engineered to express ultralong CDRH3 domains on a human antibody framework. Management will provide an overview of this innovative and pioneering technology platform, its market use and applications, as well as its strategic importance to the business. Conference Call and Webcast Information What: OmniUltra Launch Virtual Investo

12/4/25 4:05:00 PM ET

$OABI

Biotechnology: Commercial Physical & Biological Resarch

Health Care

OmniAb To Present High-Throughput Single B-cell Screening xPloration Data At The 20th Annual PEGS Boston Summit

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$OABI

OmniAb To Present High-Throughput Single B-cell Screening xPloration Data At The 20th Annual PEGS Boston Summit

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$OABI

$OABI
Insider Trading

Chief Legal Officer Berkman Charles S converted options into 18,750 shares and sold $16,541 worth of shares (9,673 units at $1.71), increasing direct ownership by 2% to 392,700 units (SEC Form 4)

Executive VP, Finance and CFO Gustafson Kurt A converted options into 18,750 shares and sold $15,905 worth of shares (9,301 units at $1.71), increasing direct ownership by 4% to 268,851 units (SEC Form 4)

President and CEO Foehr Matthew W converted options into 58,333 shares and sold $52,742 worth of shares (30,843 units at $1.71), increasing direct ownership by 0.63% to 4,403,277 units (SEC Form 4)

$OABI
Insider Purchases

Director Higgins John L bought $107,707 worth of shares (77,261 units at $1.39), increasing direct ownership by 3% to 2,929,148 units (SEC Form 4)

Director Cochran Jennifer R. bought $45,600 worth of shares (30,000 units at $1.52), increasing direct ownership by 26% to 145,274 units (SEC Form 4)

Director Love Steven bought $36,500 worth of shares (25,000 units at $1.46), increasing direct ownership by 188% to 38,333 units (SEC Form 4)

$OABI
SEC Filings

$OABI
Press Releases

$OABI
Analyst Ratings

SEC Form 144 filed by OmniAb Inc.

SEC Form 144 filed by OmniAb Inc.

SEC Form 144 filed by OmniAb Inc.

OmniAb to Report Fourth Quarter 2025 Financial Results on March 4

Launch of OmniUltra Expands OmniAb's Reach into New Markets and Applications, Advances Leadership in Antibody Discovery Technologies

Platform Technologies Drive $211B Surge in Precision Cancer Treatment

RBC Capital Mkts initiated coverage on OmniAb with a new price target

The Benchmark Company initiated coverage on OmniAb with a new price target

Craig Hallum initiated coverage on OmniAb with a new price target

$OABI
Financials

OmniAb to Report Fourth Quarter 2025 Financial Results on March 4

Launch of OmniUltra Expands OmniAb's Reach into New Markets and Applications, Advances Leadership in Antibody Discovery Technologies

OmniAb to Hold OmniUltra Virtual Investor Event on December 15

$OABI
Leadership Updates

OmniAb Appoints Steve Love to its Board of Directors

$OABI
Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by OmniAb Inc.

Amendment: SEC Form SC 13D/A filed by OmniAb Inc.

OmniAb To Present High-Throughput Single B-cell Screening xPloration Data At The 20th Annual PEGS Boston Summit

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $OABI

OmniAb To Present High-Throughput Single B-cell Screening xPloration Data At The 20th Annual PEGS Boston Summit

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $OABI

$OABI Insider Trading

Chief Legal Officer Berkman Charles S converted options into 18,750 shares and sold $16,541 worth of shares (9,673 units at $1.71), increasing direct ownership by 2% to 392,700 units (SEC Form 4)

Executive VP, Finance and CFO Gustafson Kurt A converted options into 18,750 shares and sold $15,905 worth of shares (9,301 units at $1.71), increasing direct ownership by 4% to 268,851 units (SEC Form 4)

President and CEO Foehr Matthew W converted options into 58,333 shares and sold $52,742 worth of shares (30,843 units at $1.71), increasing direct ownership by 0.63% to 4,403,277 units (SEC Form 4)

$OABI Insider Purchases

Director Higgins John L bought $107,707 worth of shares (77,261 units at $1.39), increasing direct ownership by 3% to 2,929,148 units (SEC Form 4)

Director Cochran Jennifer R. bought $45,600 worth of shares (30,000 units at $1.52), increasing direct ownership by 26% to 145,274 units (SEC Form 4)

Director Love Steven bought $36,500 worth of shares (25,000 units at $1.46), increasing direct ownership by 188% to 38,333 units (SEC Form 4)

$OABI SEC Filings

$OABI Press Releases

$OABI Analyst Ratings

SEC Form 144 filed by OmniAb Inc.

SEC Form 144 filed by OmniAb Inc.

SEC Form 144 filed by OmniAb Inc.

OmniAb to Report Fourth Quarter 2025 Financial Results on March 4

Launch of OmniUltra Expands OmniAb's Reach into New Markets and Applications, Advances Leadership in Antibody Discovery Technologies

Platform Technologies Drive $211B Surge in Precision Cancer Treatment

RBC Capital Mkts initiated coverage on OmniAb with a new price target

The Benchmark Company initiated coverage on OmniAb with a new price target

Craig Hallum initiated coverage on OmniAb with a new price target

$OABI Financials

OmniAb to Report Fourth Quarter 2025 Financial Results on March 4

Launch of OmniUltra Expands OmniAb's Reach into New Markets and Applications, Advances Leadership in Antibody Discovery Technologies

OmniAb to Hold OmniUltra Virtual Investor Event on December 15

$OABI Leadership Updates

OmniAb Appoints Steve Love to its Board of Directors

$OABI Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by OmniAb Inc.

Amendment: SEC Form SC 13D/A filed by OmniAb Inc.

Recent Analyst Ratings for
$OABI

Recent Analyst Ratings for
$OABI

$OABI
Insider Trading

$OABI
Insider Purchases

$OABI
SEC Filings

$OABI
Press Releases

$OABI
Analyst Ratings

$OABI
Financials

$OABI
Leadership Updates

$OABI
Large Ownership Changes